Bamlanivimab is a medication that FDA and Health Canada are allowing to be given for emergency/interim use to treat COVID-19. In the US, bamlanivimab is given in combination with another medication (etesevimab). Bamlanivimab is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 10 days, and are not hospitalized. To receive bamlanivimab, you must also be at high risk for COVID-19 complications, such as due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with bamlanivimab.In the US, bamlanivimab (given along with etesevimab) is also being allowed to be used to help prevent COVID-19 infection in people who have a high risk for infection after exposure to someone infected with COVID-19. Some conditions that increase risk of infection after exposure include: not being fully vaccinated, having had close contact, or being at high risk of close contact due to your housing conditions (such as a nursing home or prison).Bamlanivimab is an antibody which, when given soon after infection, can neutralize the coronavirus and may prevent worsening of COVID-19 symptoms. More information about the combination of bamlanivimab with etesevimab is available from the FDA Fact Sheet for Patients, Parents and Caregivers for Emergency Use. More information about bamlanivimab is available from the Health Canada Patient Medication Information sheet. If you are enrolled in a study, information should be provided by the doctor via the Informed Consent Form.There is limited information about how safe and effective bamlanivimab is for treating COVID-19. Study results show that bamlanivimab may help people who have recently tested positive for coronavirus stay out of the hospital. Bamlanivimab is not for use by people who are hospitalized due to COVID-19, or who need supplemental oxygen or a ventilator due to COVID-19.The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of bamlanivimab, and it is always the responsibility of treating practitioners to exercise independent judgment in making care decisions.

How to use Bamlanivimab 700 Mg/20 Ml (35 Mg/Ml) Intravenous Solution (EUA) Antiviral Monoclonal Antibodies - SARS-Cov-2 Coronavirus

Bamlanivimab is given one time by injection into a vein by a healthcare professional. It is infused over 16 to 60 minutes. When bamlanivimab is given in combination with etesevimab, it is infused over 16 to 70 minutes. A healthcare professional will observe you during your infusion and for at least another hour after your treatment in case you have serious side effects.

Tell your doctor if your condition does not improve or if it gets worse.

Side Effects

Pain, soreness, swelling, or bruising at the injection site may occur. If you notice any of these effects, tell your healthcare professional promptly.

An infusion reaction may occur while bamlanivimab is being given, causing symptoms such as low or high blood pressure, dizziness, slow/fast/irregular heartbeat, chest pain, trouble breathing, fever, chills, nausea, headache, confusion, sweating, or muscle pain. Get medical help right away if you notice any of these symptoms. A slower rate of infusion may help to lessen the risk of this reaction.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Information is limited and it is unknown at this time if bamlanivimab causes other serious side effects. This is not necessarily a complete list of possible side effects.

Contact your doctor for medical advice about side effects.


Before using this medication, tell your doctor if you have any allergies. Bamlanivimab may contain inactive ingredients, which can cause allergic reactions or other problems.

Limited information is known at this time about other medical conditions that may affect how bamlanivimab works or how bamlanivimab may affect other medical conditions.

Before using this medication, tell your doctor your medical history.

To avoid spreading the virus, you should continue to take precautions such as self-isolation, wearing a mask, social distancing (physical distancing), washing hands, and not sharing personal items.

Tell your doctor if you are pregnant or think you are pregnant. Bamlanivimab should be used during pregnancy only if the possible benefits are greater than the possible risks.

It is unknown if bamlanivimab passes into breast milk. The risks of breast-feeding while infected with COVID-19 and while using bamlanivimab should be discussed with the doctor.


Drug interactions may change how medications work or increase the risk for serious side effects. Information is limited and it is unknown at this time if bamlanivimab has drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor. Do not start, stop or change the dosage of any medicine without your doctor's approval.

Does Bamlanivimab 700 Mg/20 Ml (35 Mg/Ml) Intravenous Solution (EUA) Antiviral Monoclonal Antibodies - SARS-Cov-2 Coronavirus interact with other drugs you are taking?
Enter your medication into the WebMD interaction checker


Overdose information is not available at this time.


Not applicable.

Missed Dose

Not applicable.


Not applicable. Bamlanivimab is not stored at home.


bamlanivimab 700 mg/20 mL (35 mg/mL) intravenous soln (1 of 2) (EUA)

bamlanivimab 700 mg/20 mL (35 mg/mL) intravenous soln (1 of 2) (EUA)

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

Free RX Coupon

Save up to 80% on your prescriptions.

Available coupons

Save up to 80% on your prescription with WebMDRx

Drug Survey

Are you currently using Bamlanivimab 700 Mg/20 Ml (35 Mg/Ml) Intravenous Solution (EUA) Antiviral Monoclonal Antibodies - SARS-Cov-2 Coronavirus?

This survey is being conducted by the WebMD marketing sciences department.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.